분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-08-31 03:22:37 , Hit : 694
 UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis

https://endpts.com/fda-ushers-in-a-new-era-in-cancer-treatment-with-game-changing-car-t-approval-for-novartis/?utm_medium=email&utm_campaign=ALERT+FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis&utm_content=ALERT+FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis+CID_b478855548eb40528cf6ab7b72a04479&utm_source=ENDPOINTS+emails&utm_term=FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis

by John Carroll — on August 30, 2017 11:07 AM EDT


The FDA has approved the world’s first CAR-T therapy, giving a green light to Novartis for Kymriah (tisagenlecleucel) in what regulators themselves describe as an historic event.

The early approval — about a month ahead of the PDUFA date — came through for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia.

Novartis set the price for the one-time treatment at $475,000, right in line with low-end estimates and one that will put pressure on Gilead to rein in its own price for a rival therapy expected to be approved in the near future.

None other than FDA commissioner Scott Gottlieb did the honors in the agency’s statement, noting:


We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer. New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.

A group of biopharma companies have been racing to this breakthrough point. Kite Pharma $KITE, newly bought out in a $12 billion deal by Gilead $GILD, is coming in a close second with its own application for axicel.

Novartis’ investigators registered a game-changing 83% remission rate in its pivotal study.

CAR-T, though, is also associated with severe and potentially deadly side effects, including lethal instances of cytokine release syndrome with some patients dying from brain swelling in separate studies from the Novartis drug.

Regulators noted that they will require special training for anyone involved in delivering this therapy, while expanding the approval of Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening CRS in patients 2 years of age or older. “In clinical trials in patients treated with CAR-T cells,” the FDA reported, “69% of patients had complete resolution of CRS within two weeks following one or two doses of Actemra.”

This therapy, which is made using a patient’s own immune cells, won’t be cheap.

By its own reckoning, the UK’s tough watch dog on drug pricing has said that these drugs would be worth up to $649,000 a year, given the young patients it’s targeting first. Analysts, meanwhile, have pegged the price at anywhere from $400,000 to $750,000.

In a call with analysts, Novartis execs said it would keep the price well below the high end, setting the cost at $475,000 for a drug that will be available in 20 centers within one month, and 35 soon after.

In a statement the company said it “is collaborating with CMS to make an outcomes-based approach available to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month. Future potential indications would be reviewed for the most relevant outcomes-based approach.”

Said Joseph Jimenez, CEO of Novartis:


Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care.

This approval marks a major shift in oncology, with a truly revolutionary approach to treating cancer. That hasn’t escaped the notice of big players and small, with a host of developers looking to do much better, more safely, with new drugs in the pipeline.

It’s a big day in the biotech world, but it’s just the official start date for a new era.







  UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 694
1026   “유전자 치료 법률 금지 한국 유일” vs “생명체 설계도 바꾸는 건 문제”  이성욱 2017/08/28 730
1025   Cancer Onset May Be Caused by Immune System Fighting Viruses  이성욱 2017/08/25 715
1024   유전자 가위로 바이러스 제거한 '청정 돼지' 나왔다  이성욱 2017/08/24 763
1023   CRISPR Corrects RNA-based Disease Defects  이성욱 2017/08/14 735
1022   Uncovering Functions of Circular RNAs  이성욱 2017/08/14 721
1021   First In Vivo Function Found for Animal Circular RNA  이성욱 2017/08/14 767
1020   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1019   Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 716
1018   [바이오토픽] 드디어 올 것이 왔다: CRISPR, 생존가능 인간배아의 질병초래 유전자 교정 성공  이성욱 2017/08/03 730
1017   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 781
1016   A Novel Mammalian Genomic Imprinting Mechanism  이성욱 2017/07/25 812
1015   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 704
1014   CRISPR Structure Data Reveal How Cas Enzymes Choose Target  이성욱 2017/07/25 1088
1013   Anti-CRISPR Protein Reduces Off-Target Effects  이성욱 2017/07/14 792
1012   CRISPR Encodes Movie into Bacteria, Then DNA Sequencing Plays It  이성욱 2017/07/14 1018
1011   [바이오토픽] CRISPR를 이용하여 세균의 DNA에 영화를 저장!  이성욱 2017/07/14 864
1010   [바이오토픽] FDA 자문위원회, CAR-T(chimeric antigen receptor T cell) 승인 만장일치로 권고  이성욱 2017/07/14 748
1009   유전자치료제 '인보사' 연골재생 입증못해도 허가받은 까닭  이성욱 2017/07/14 744
1008   코오롱 인보사허가  이성욱 2017/07/12 704

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN